Cancer associated macrophage-like cells and prognosis of esophageal cancer after chemoradiation therapy

Journal of Translational Medicine

Cha-Mei Tang¹  Daniel L. Adams²  Jianzhong He³  Yawei Qiao³  Ritsuko Komaki³  Steven H. Lin³  Ting Xu³  Hui Gao³  Zhongxing Liao³  James M. Reuben³  Mariela Blum-Murphy⁴  Daniel J. Gironda⁵  Wayne L. Hofstetter⁶ 

[1] Creatv MicroTech Inc, 9900 Belward Campus Dr, 20850, Rockville, MD, USA;Creatv MicroTech Inc, Monmouth Junction, 9 Deer Park Dr, 08852, Potomac, NJ, USA;Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA;Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA;Rutgers, The State University of New Jersey, 77 Hamilton Street, 08901, New Brunswick, NJ, USA;Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA;

关键词: Esophageal cancer;    Cancer associated macrophage-like cell;    Prognostic;    Biomarker;   

DOI  :  10.1186/s12967-020-02563-x

来源: Springer

【 摘 要 】

BackgroundCancer Associated Macrophage-Like cells (CAMLs) are polynucleated circulating stromal cells found in the bloodstream of numerous solid-tumor malignancies. Variations within CAML size have been associated with poorer progression free survival (PFS) and overall survival (OS) in a variety of cancers; however, no study has evaluated their clinical significance in esophageal cancer (EC).MethodsTo examine this significance, we ran a 2 year prospective pilot study consisting of newly diagnosed stage I-III EC patients (n = 32) receiving chemoradiotherapy (CRT). CAML sizes were sequentially monitored prior to CRT (BL), ~ 2 weeks into treatment (T1), and at the first available sample after the completion of CRT (T2).ResultsWe found CAMLs in 88% (n = 28/32) of all patient samples throughout the trial, with a sensitivity of 76% (n = 22/29) in pre-treatment screening samples. Improved 2 year PFS and OS was found in patients with CAMLs < 50 μm by the completion of CRT over patients with CAMLs ≥ 50 μm; PFS (HR = 12.0, 95% CI = 2.7–54.1, p = 0.004) and OS (HR = 9.0, 95%CI = 1.9–43.5, p = 0.019).ConclusionsTracking CAML sizes throughout CRT as a minimally invasive biomarker may serve as a prognostic tool in mapping EC progression, and further studies are warranted to determine if presence of these cells prior to treatment suggest diagnostic value for at-risk populations.

【 授权许可】

CC BY